[go: up one dir, main page]

UA89780C2 - Способ лечения или облегчения симптомов атеросклероза с помощью анти-cd3 антитела - Google Patents

Способ лечения или облегчения симптомов атеросклероза с помощью анти-cd3 антитела

Info

Publication number
UA89780C2
UA89780C2 UAA200611467A UAA200611467A UA89780C2 UA 89780 C2 UA89780 C2 UA 89780C2 UA A200611467 A UAA200611467 A UA A200611467A UA A200611467 A UAA200611467 A UA A200611467A UA 89780 C2 UA89780 C2 UA 89780C2
Authority
UA
Ukraine
Prior art keywords
atherosclerosis
antibody
treating
alleviating symptoms
alleviating
Prior art date
Application number
UAA200611467A
Other languages
English (en)
Ukrainian (uk)
Inventor
Бернар Мах
Ян Дин
Мари Коско-Вильбуа
Original Assignee
Новиммюн С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новиммюн С.А. filed Critical Новиммюн С.А.
Publication of UA89780C2 publication Critical patent/UA89780C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к способу лечения или облегчения симптомов атеросклероза, а также способа подавления образования атеросклеротических бляшек на артериях с помощью анти-CD3 антитела.
UAA200611467A 2004-04-06 2005-04-06 Способ лечения или облегчения симптомов атеросклероза с помощью анти-cd3 антитела UA89780C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55994404P 2004-04-06 2004-04-06

Publications (1)

Publication Number Publication Date
UA89780C2 true UA89780C2 (ru) 2010-03-10

Family

ID=35150504

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200611467A UA89780C2 (ru) 2004-04-06 2005-04-06 Способ лечения или облегчения симптомов атеросклероза с помощью анти-cd3 антитела
UAA200907841A UA103594C2 (ru) 2004-04-06 2005-04-06 Способ лечения увеита

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA200907841A UA103594C2 (ru) 2004-04-06 2005-04-06 Способ лечения увеита

Country Status (19)

Country Link
US (1) US20050265993A1 (ru)
EP (1) EP1737490B1 (ru)
JP (1) JP4812748B2 (ru)
KR (1) KR20070036035A (ru)
CN (2) CN1972714B (ru)
AT (1) ATE470453T1 (ru)
AU (1) AU2005232653B2 (ru)
CA (1) CA2563260C (ru)
DE (1) DE602005021766D1 (ru)
DK (1) DK1737490T3 (ru)
EA (1) EA012725B1 (ru)
ES (1) ES2348984T3 (ru)
IL (2) IL178478A (ru)
MX (1) MXPA06011526A (ru)
NO (2) NO340627B1 (ru)
PT (1) PT1737490E (ru)
UA (2) UA89780C2 (ru)
WO (1) WO2005099755A2 (ru)
ZA (1) ZA200608884B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4939899B2 (ja) * 2006-10-30 2012-05-30 オムロンオートモーティブエレクトロニクス株式会社 導電端子の溶接方法、および導電端子構造
RS58217B1 (sr) † 2007-04-03 2019-03-29 Amgen Res Munich Gmbh Interspecijski specifičan vezujući domen
JP2013526594A (ja) * 2010-05-24 2013-06-24 インデナ エッセ ピ ア 微生物感染の治療に使用するためのタマリンド種子多糖
WO2012066058A1 (en) * 2010-11-16 2012-05-24 Boehringer Ingelheim International Gmbh Agents and methods for treating diseases that correlate with bcma expression
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
JP2015091761A (ja) * 2012-02-23 2015-05-14 国立大学法人大阪大学 中枢神経の損傷を治療するための組成物およびその利用
US9664690B1 (en) * 2013-08-28 2017-05-30 The National Institute For Biotechnology I Molecular diagnostic kits for evaluating stress
KR20200136977A (ko) 2018-03-28 2020-12-08 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 엑소좀으로부터 단리된 dna에서의 후성유전학적 변화의 식별
US20220144926A1 (en) * 2018-10-16 2022-05-12 Board Of Regents, The University Of Texas System Identification and targeting of pathogenic extracellular matrix for diagnosis and treatment of cancer and other diseases
EP3873521A2 (en) 2018-10-31 2021-09-08 Tiziana Life Sciences PLC Composition and methods of treating inflammatory and autoimmune diseases
US12122850B2 (en) 2022-03-14 2024-10-22 LamKap Bio gamma AG Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025477A (en) * 1986-03-31 2000-02-15 Calenoff; Emanuel Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
WO1994026303A1 (en) * 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US7041289B1 (en) * 1997-12-05 2006-05-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for treating established spontaneous auto-immune diseases in mammals
GB2380127A (en) * 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
US20030216551A1 (en) * 2002-03-08 2003-11-20 Diabetogen Biosciences Inc. Fully human anti-CD3 monoclonal antibodies
AU2005206746B2 (en) * 2004-01-08 2008-08-28 Regents Of The University Of California Regulatory t cells suppress autoimmunity

Also Published As

Publication number Publication date
US20050265993A1 (en) 2005-12-01
CN1972714B (zh) 2012-10-03
ATE470453T1 (de) 2010-06-15
WO2005099755A3 (en) 2006-04-27
ZA200608884B (en) 2008-06-25
ES2348984T3 (es) 2010-12-21
CA2563260A1 (en) 2005-10-27
HK1099525A1 (en) 2007-08-17
IL178478A (en) 2010-12-30
UA103594C2 (ru) 2013-11-11
JP4812748B2 (ja) 2011-11-09
EA012725B1 (ru) 2009-12-30
AU2005232653B2 (en) 2010-12-16
CN1972714A (zh) 2007-05-30
MXPA06011526A (es) 2007-03-21
KR20070036035A (ko) 2007-04-02
PT1737490E (pt) 2010-08-31
DE602005021766D1 (de) 2010-07-22
EA200601871A1 (ru) 2007-04-27
CN102847149B (zh) 2016-01-20
IL178478A0 (en) 2007-02-11
DK1737490T3 (da) 2010-10-04
JP2007532565A (ja) 2007-11-15
EP1737490A2 (en) 2007-01-03
IL209338A0 (en) 2011-01-31
EP1737490B1 (en) 2010-06-09
NO20170737A1 (no) 2006-11-06
NO340627B1 (no) 2017-05-15
WO2005099755A2 (en) 2005-10-27
CA2563260C (en) 2013-05-28
CN102847149A (zh) 2013-01-02
AU2005232653A1 (en) 2005-10-27
NO20064896L (no) 2006-11-06

Similar Documents

Publication Publication Date Title
WO2005007192A3 (en) Cytoprotection through the use of hif hydroxylase inhibitors
UA92505C2 (ru) Композиции на основе антитела против cd3
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
TW200738270A (en) Method of treating depression using a TNFα antibody
WO2009021754A3 (en) Monospecific and multispecific antibodies and method of use
WO2006116423A3 (en) Compositions and methods for cancer immunotherapy
WO2009126934A3 (en) Detection and tratment of pancreatic, ovarian and other cancers
MX2010006823A (es) Metodos para el tratamiento de la gota.
UA104132C2 (en) Humanized antibodies against tl1a
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
MY147217A (en) Antibody molecules having specificity for human il-06
TW200605907A (en) Preventing autoimmune disease
WO2004099249A3 (en) Optimized fc variants and methods for their generation
WO2006085967A3 (en) OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
MX2009001983A (es) Compuesto que contiene dioxido de titanio.
MX2009013410A (es) Biomarcadores para predecir capacidad de respuesta anti-tnf o sin capacidad de respuesta.
IL182716A0 (en) Method for purifying fsh
NZ616382A (en) Antibodies specific to cadherin-17
WO2006130399A3 (en) Therapeutic combinations and methods including irm compounds
SG132645A1 (en) Process for the production of polyols based on natural oils
WO2008043052A3 (en) Human antibodies neutralizing human metapneumovirus
MX2011012666A (es) Usos de anticuerpos il-1beta y sus fragmentos de union relacionados con eventos cardiovasculares.
UA89780C2 (ru) Способ лечения или облегчения симптомов атеросклероза с помощью анти-cd3 антитела
WO2006021955A3 (en) Use of bat monoclonal antibody for immunotherapy
TW200613256A (en) Photoactive compounds